Breaking News

Emergent Signs $14.5M COVID-19 BARDA Deal

Partners with U.S. government for comprehensive response to expedite development of plasma-derived therapy for COVID-19

By: Contract Pharma

Contract Pharma Staff

Emergent BioSolutions has entered into a formal partnership with the U.S. government to expedite development of a plasma-derived therapy for patients with coronavirus disease 2019 (COVID-19). Emergent has received $14.5 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS), in support of its COVID-HIG program, one of two hyperim...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters